ERBB2 and breast carcinoma: It realized the visualization of CDK4 activity in living cells and in vivo, and initially assessed the therapeutic efficacy of CDK4 inhibitors in the treatment of HR+/HER2‐ breast cancer in pre‐clinical experiments.